KODIAK SCIENCES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.81 USD | +1.81% |
|
-2.77% | -7.57% |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 147M |
|---|---|---|---|---|---|
| Net income 2024 * | -184M | Net income 2025 * | -240M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 98.72M | Net Debt 2025 * | 8.24M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-0.79
x | P/E ratio 2025 * |
-0.71
x | Employees | 107 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.34% |
More Fundamentals
* Assessed data
More news
Latest transcript on Kodiak Sciences Inc.
More recommendations
More press releases
| 1 day | +1.81% | ||
| 1 week | -2.77% | ||
| Current month | -11.64% | ||
| 1 month | -26.82% | ||
| 3 months | -50.04% | ||
| 6 months | -8.77% | ||
| Current year | -7.57% |
1 week
2.67
3.06
1 month
2.673.89
Current year
2.677.77
1 year
1.379.29
3 years
1.37131.97
5 years
1.37171.21
10 years
1.37171.21
| Managers | Title | Age | Since |
|---|---|---|---|
Victor Perlroth
CEO | Chief Executive Officer | 51 | 08-12-31 |
John Borgeson
DFI | Director of Finance/CFO | 62 | 15-12-31 |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Felix Baker
BRD | Director/Board Member | 55 | 15-08-31 |
Tai Yin Yang
BRD | Director/Board Member | 70 | 19-12-16 |
Richard Levy
BRD | Director/Board Member | 66 | 18-07-17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - | |
| 0.03% | 0 M€ | 0.00% | - | |
| 0.00% | 9 M€ | +9.76% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-14 | 2.81 | +1.81% | 194,133 |
| 24-06-13 | 2.76 | -1.08% | 128,237 |
| 24-06-12 | 2.79 | -1.06% | 149,527 |
| 24-06-11 | 2.82 | +1.44% | 143,088 |
| 24-06-10 | 2.78 | -3.81% | 465,259 |
Delayed Quote Nasdaq, June 14, 2024 at 04:00 pm EDT
More quotes
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Calendar
2024-08-11
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
2.81
USD
Average target price
3.5
USD
Spread / Average Target
+24.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.57% | 147M | |
| +18.15% | 124B | |
| +18.02% | 112B | |
| -12.75% | 22.22B | |
| +5.07% | 22.94B | |
| -39.94% | 16.87B | |
| -9.86% | 17.02B | |
| -14.97% | 16.88B | |
| +2.80% | 13.63B | |
| +27.39% | 11.61B |
- Stock Market
- Equities
- KOD Stock
